Organigram's US$411.4M Aurora deal tops Curaleaf's hostile bid
What's the deal? OrganigramDealroom has a profile for this one. Try Dealroom → has agreed to acquire fellow Canadian cannabis producer Aurora CannabisDealroom has a profile for this one. Try Dealroom → for US$5.72 per share, valuing Aurora at about US$411.4M on a fully diluted basis. Aurora shareholders can take cash, Organigram shares, or a mix, subject to proration. Both boards back the deal unanimously.
Why now? The agreement ends a live takeover contest. Aurora's board had unanimously rejected a revised hostile bid from Curaleaf, worth about US$5 per share, while reviewing alternatives. Organigram's offer is a 21% premium to that bid and a 93% premium to Aurora's unaffected share price on August 10, 2026.
What's the endgame? The two companies aim to build a global cannabis leader spanning Canada, Europe, and Australia. The combined entity would own five EU-GMP certified production and distribution facilities, pairing Organigram's Canadian recreational scale with Aurora's international medical business.
Organigram completed its acquisition of Germany's Sanity Group in April, extending the European foothold that Aurora's EU-GMP capacity would reinforce. It also counts British American Tobacco subsidiary BT DE InvestmentsDealroom has a profile for this one. Try Dealroom → as a cornerstone shareholder.
What did Curaleaf say? The world's largest cannabis company, with a market cap of about $2.6 billion, was blunt. "We are outraged, and Aurora shareholders should be too," it said, arguing it had been denied due diligence access while "a small Canadian company" was welcomed into the process.
What could go wrong? The deal depends on execution and regulatory approvals. Organigram's financing — including the BAT investment — will be worth watching given the scale of the purchase.
The signal: This is less a straight domestic roll-up than a bet on international medical cannabis. By combining recreational scale, a European base, and global medical reach, Organigram is positioning against Curaleaf's US-led model — and raising the stakes in a consolidating industry.
Read more: markets.financialcontent.com
Image credit: Generated with Gemini
